August 2026 Monthly Content Release Notes Copied
Lab Analytes & Panels
Summary
This release includes 26 newly created panels and 32 newly created analytes. Four existing panels were updated, and 1 existing analyte was updated.
Additions
- Adalimumab AB, IBD, AU
- Adalimumab Comment
- Aldolase, U/L
- Alpha-tryptase copy number
- ANA interpretive comment
- Anti-gp210 antibody, IgG, units
- Anti-sp100 antibody, IgG, units
- Antinuclear antibody (ANA), HEp-2, IgG
- Antithrombin III activity, % normal
- Asialo-GM1 antibodies panel
- Asialo-GM1 antibodies, IgG/IgM
- Beta-tryptase copy number
- Blastomyces Ab, complement fixation, serum panel
- Borrelia burgdorferi DNA, RT PCR, qual
- CK+LD+Aldola panel
- Custom Alpha-gal panel
- Desoxycortisol (Compound S), S
- Desoxycortisol panel
- F041-IgE Salmon panel
- F041-IgE Salmon, kU/L
- F414-IgE Tilapia panel
- F414-IgE Tilapia, kU/L
- Foundation Ventana PTEN (SP218) panel
- FoundationOne germlineMore panel
- FoundationOne monitor panel
- FoundationOne PGx panel
- FoundationOne PGx panel
- Galactose a-1, 3-galactose CapE
- GD1a antibodies, IgG/IgM
- GD1b antibodies, IgG/IgM
- GeneSeq cardio single gene analysis panel
- GM1 antibodies, IgG/IgM
- GM1 Antibody IgG, IgM panel
- GM2 antibodies, IgG/IgM
- GQ1b antibodies, IgG/IgM
- Guardant360 liquid CDx
- HER-2/neu IHC, gastric, paraffin panel
- HLA-B27 Ag, flow cytometry
- Invitae complement deficiency disorders panel
- Invitae progressive renal disease panel
- Lamb (F88), IgE class
- Liquid Set (FoundationOne Liquid CDx + FoundationOne Liquid) panel
- LP-IR score
- Macroscopic exam arthropod
- Macroscopic exam arthropod panel
- NorthStar response panel
- NorthStar select panel
- PK enzyme activity, U/g Hb
- POC glucose, mg/L
- Reticulocyte profile panel
- Ribosomal P IgG, U/mL
- Selenium RBC panel
- Selenium RBC, ug/dL
- Tempus comprehensive therapy selection xT+xR + IHC panel
- Tissue Set (FoundationOne CDx + FoundationOne Tissue + FoundationOne RNA) panel
- TPSAB1 genetic panel
- TPSAB1 interp
- TPSAB1, source
Updates
- Adalimumab drug + antibody panel
- ALT (SGPT) P5P (NASH), IU/L
- FoundationOne germline panel
- NMR LipoProfile panel
- Tick-borne panel by RT-PCR (Non-NY)
Medications
Additions
- Fianlimab-Cemiplimab invest (REGN3767-REGN2810 invest IV)
- HLD-0915 (JNJ-101556143) invest Oral
- Investigational Study drug invest – ophthalmic
- Mocertatug rezetecan invest (GSK5733584 invest IV)
- NEOK002 invest IV
- NRM-823 invest IV
- RMC-5127 invest Oral
Updates
| Medications | Updates |
| AAA817 invest (225Ac Ac-PSMA-617 invest IV) | New Form available:
|
| Alnodesertib invest (ART0380 invest Oral) | New Alias available:
|
| Elranatamab invest Subcutaneous | New Form available:
|
| [F-18]-FAPI-74 invest IV | Updated Form:
|
| Izalontamab Brengitecan invest (BMS-986507 invest IV) | New Form available:
|
| Sacituzumab tirumotecan invest (MK-2870, sac-TMT invest IV) | New Name available:
|
| Sofetabart Mipitecan invest (LY4170156 invest IV) | New Alias available:
|
Regimens
Additions
| Regimen Name | Diagnosis |
| Daratumumab SQ + Lenalidomide + Bortezomib D1,4,8,11 + Dexamethasone (RVD) Q21D (Transplant Candidates) | Multiple Myeloma (MM) |
| Fam-Trastuzumab Deruxtecan (Enhertu) fb Paclitaxel D1,8,15 + Pertuzumab and Trastuzumab SQ (Phesgo) Q21D | Breast Cancer |
| Floxuridine HAI Q28D | Colon Cancer; Rectal Cancer; Bile Duct Cancer (Parent) |
| Paclitaxel D1,8,15 + Pertuzumab and Trastuzumab SQ (Phesgo) fb Fam-Trastuzumab Deruxtecan (Enhertu) Q21D | Breast Cancer |
| Paclitaxel D1,8,15 + Pertuzumab IV + Trastuzumab IV fb Fam-Trastuzumab Deruxtecan (Enhertu) Q21D | Breast Cancer |
| Pembrolizumab IV + Belzutifan Q42D | Renal Cell Carcinoma (RCC) |
| Pembrolizumab SQ + Belzutifan Q42D | Renal Cell Carcinoma (RCC) |
| Tafasitamab + Lenalidomide + Rituximab IV + CHOP Q21D | Lymphoma, Non-Hodgkin (NHL) (Parent) |
| Teclistamab (Tecvayli) D1,3,5, Step Up fb Maintenance (2nd Line+, MajesTEC-9) | Multiple Myeloma (MM) |
| Venetoclax + Decitabine and Cedazuridine (Inqovi) D1-5 Q28D (AML) | Leukemia, Acute Myeloid (AML) |
| Isatuximab SQ + Carfilzomib D1,2,8,9,15,16 + Dexamethasone Q28D | Multiple Myeloma (MM) |
| Isatuximab SQ + Lenalidomide + Bortezomib + Dexamethasone (RVD) Q28D (non-transplant candidates) | Multiple Myeloma (MM) |
| Isatuximab SQ + Pomalidomide + Dexamethasone Q28D | Multiple Myeloma (MM) |
Updates
- Curbside Connect problem group updates:
- All Problems
- Bladder Cancer
- Breast Cancer
- Esophageal Cancer
- Gastric Cancer
- Leukemia, Acute Lymphocytic (ALL)
- Leukemia, Chronic Lymphocytic (CLL)
- Lung Cancer, Non-small Cell (NSCLC)
- Lung Cancer, Small Cell (SCLC)
- Lymphoma, Non-Hodgkin (NHL) (Parent)
- Multiple Myeloma (MM)
- Myelofibrosis
- Myeloproliferative Disorder
- Renal Pelvis and Ureter Cancer
- Urethral Cancer
- Uterine Cancer
Renames
| Previous Name | New Name |
| Epcoritamab-bysp (Epkinly) SQ D1,8,15,22 fb D1 + Lenalidomide D1-21 + Rituximab IV C1-5 Q28D | Epcoritamab (Epkinly) SQ D1,8,15,22 fb D1 + Lenalidomide D1-21 + Rituximab IV C1-5 Q28D |
| Epcoritamab-bysp (Epkinly) SQ D1,8,15,22 fb D1,15 fb D1 Q28D (DLBCL) | Epcoritamab (Epkinly) SQ D1,8,15,22 fb D1,15 fb D1 Q28D (DLBCL) |
| Epcoritamab-bysp (Epkinly) SQ D1,8,15,22 fb D1,15 fb D1 Q28D (FL) | Epcoritamab (Epkinly) SQ D1,8,15,22 fb D1,15 fb D1 Q28D (FL) |
| Epcoritamab-bysp (Epkinly) SQ D1,8,15,22 fb D1,15 fb D1 + Gemcitabine + Oxaliplatin (GemOx) C1-4 D1,15 Q28D | Epcoritamab (Epkinly) SQ D1,8,15,22 fb D1,15 fb D1 + Gemcitabine + Oxaliplatin (GemOx) C1-4 D1,15 Q28D |
| Fludarabine (25 mg/m2) + Cyclophosphamide (250 mg/m2) D1-3 (CAR T-cell Therapy Lymphodepletion) | Fludarabine + Cyclophosphamide (Kymriah Lymphodepletion) |
| Fludarabine (30 mg/m2) + Cyclophosphamide (300 mg/m2) D1-3 (CAR T-cell Therapy Lymphodepletion) | Fludarabine + Cyclophosphamide (Breyanzi, Carvykti, & Abecma Lymphodepletion) |
| Nivolumab + Ipilimumab + Paclitaxel + Carboplatin Q21D | Nivolumab + Ipilimumab + Paclitaxel + Carboplatin Q21D fb Nivolumab + Ipilimumab Maintenance |
| Nivolumab + Ipilimumab + Pemetrexed + Carboplatin Q21D | Nivolumab + Ipilimumab + Pemetrexed + Carboplatin Q21D fb Nivolumab + Ipilimumab Maintenance |
| Polatuzumab Vedotin D1 + Mosunetuzumab-axgb SQ (Lunsumio Velo) D1,8,15 fb D1 Q21D | Polatuzumab Vedotin D1 + Mosunetuzumab SQ (Lunsumio Velo) D1,8,15 fb D1 Q21D |
| Polatuzumab Vedotin D1 + Mosunetuzumab (Lunsumio) D1,8,15 fb D1 Q21D | Polatuzumab Vedotin D1 + Mosunetuzumab IV (Lunsumio) D1,8,15 fb D1 Q21D |
| Ruxolitinib + Luspatercept-aamt Q21D (Myelofibrosis) | Ruxolitinib + Luspatercept Q21D (Myelofibrosis) |
| Sacituzumab govitecan-hziy D1,8 Q21D | Sacituzumab govitecan D1,8 Q21D |
| Tarlatamab-dlle (Imdelltra) D1,8,15 fb D1,15 Q28D | Tarlatamab (Imdelltra) D1,8,15 fb D1,15 Q28D |
| Teclistamab-cqyv (Tecvayli) SQ D1,3,5 (Initial) | Teclistamab (Tecvayli) SQ Option D1,3,5 (Initial) |
| Teclistamab-cqyv (Tecvayli) SQ D1,4,7 (Initial) | Teclistamab (Tecvayli) SQ D1,4,7 (Initial) |
Removals
| Regimen Name | Diagnosis |
| Ribociclib D1-21 + Tamoxifen + Goserelin Q28D | Breast Cancer |
| Ribociclib D1-21 + Tamoxifen + Leuprolide Q28D | Breast Cancer |
| Ribociclib D1-21 + Tamoxifen Q28D | Breast Cancer |
Billing & HCPCS Codes
Summary
Billing codes (HCPCS) – including additions, updates — to support iKnowMed Generation 2 (G2) Production with the most current clinical billing content.
Additions
| Medication | Codes |
| Gedatolisib IV | J9999 per 180 mg |
| Isatuximab-irfc Subcutaneous | J3590 per 1400 mg |
| Ropeginterferon alfa-2b-njft Subcutaneous Pen Injector | J9999 per 100 mcg |
Therapeutic Interchange Management
Summary
Details about recent content updates for Therapeutic Interchange Management content groups can be found on the Ontada Guide Site.
ICD-10-CM
Additions
The following codes and descriptions will be effective October 1, 2026:
| Code | Description |
| R78.72 | Abnormal gadolinium level in blood |
| I42.81 | Arrhythmogenic cardiomyopathy |
| Z68.18 | Body mass index [BMI] 18.4 or less, adult |
| Z68.19 | Body mass index [BMI] 18.5-19.9, adult |
| I49.81 | Brugada syndrome |
| L02.237 | Carbuncle of flank |
| I47.22 | Catecholaminergic polymorphic ventricular tachycardia [CPVT] |
| O00.4 | Cervical ectopic pregnancy |
| O00.42 | Cervical ectopic pregnancy with intrauterine pregnancy |
| O00.41 | Cervical ectopic pregnancy without intrauterine pregnancy |
| O00.3 | Cesarean scar ectopic pregnancy |
| O00.32 | Cesarean scar ectopic pregnancy with intrauterine pregnancy |
| O00.31 | Cesarean scar ectopic pregnancy without intrauterine pregnancy |
| Z77.33 | Contact with and (suspected) exposure to Agent Orange |
| Z77.4 | Contact with and (suspected) exposure to blast overpressure |
| Z77.32 | Contact with and (suspected) exposure to burn pits in war theater |
| Z77.013 | Contact with and (suspected) exposure to gadolinium |
| Z77.42 | Contact with and (suspected) exposure to high-level blast overpressure |
| Z77.41 | Contact with and (suspected) exposure to low-level blast overpressure |
| Z77.49 | Contact with and (suspected) exposure to other blast overpressure |
| Z77.40 | Contact with and (suspected) exposure to unspecified blast overpressure |
| O31.4 | Continuing pregnancy after vanishing twin syndrome of one fetus or more |
| O31.41 | Continuing pregnancy after vanishing twin syndrome of one fetus or more, first trimester |
| O31.41×1 | Continuing pregnancy after vanishing twin syndrome of one fetus or more, first trimester, fetus 1 |
| O31.41×2 | Continuing pregnancy after vanishing twin syndrome of one fetus or more, first trimester, fetus 2 |
| O31.41×3 | Continuing pregnancy after vanishing twin syndrome of one fetus or more, first trimester, fetus 3 |
| O31.41×4 | Continuing pregnancy after vanishing twin syndrome of one fetus or more, first trimester, fetus 4 |
| O31.41×5 | Continuing pregnancy after vanishing twin syndrome of one fetus or more, first trimester, fetus 5 |
| O31.41×0 | Continuing pregnancy after vanishing twin syndrome of one fetus or more, first trimester, not applicable or unspecified |
| O31.41×9 | Continuing pregnancy after vanishing twin syndrome of one fetus or more, first trimester, other fetus |
| O31.42 | Continuing pregnancy after vanishing twin syndrome of one fetus or more, second trimester |
| O31.42×1 | Continuing pregnancy after vanishing twin syndrome of one fetus or more, second trimester, fetus 1 |
| O31.42×2 | Continuing pregnancy after vanishing twin syndrome of one fetus or more, second trimester, fetus 2 |
| O31.42×3 | Continuing pregnancy after vanishing twin syndrome of one fetus or more, second trimester, fetus 3 |
| O31.42×4 | Continuing pregnancy after vanishing twin syndrome of one fetus or more, second trimester, fetus 4 |
| O31.42×5 | Continuing pregnancy after vanishing twin syndrome of one fetus or more, second trimester, fetus 5 |
| O31.42×0 | Continuing pregnancy after vanishing twin syndrome of one fetus or more, second trimester, not applicable or unspecified |
| O31.42×9 | Continuing pregnancy after vanishing twin syndrome of one fetus or more, second trimester, other fetus |
| O31.43 | Continuing pregnancy after vanishing twin syndrome of one fetus or more, third trimester |
| O31.43×1 | Continuing pregnancy after vanishing twin syndrome of one fetus or more, third trimester, fetus 1 |
| O31.43×2 | Continuing pregnancy after vanishing twin syndrome of one fetus or more, third trimester, fetus 2 |
| O31.43×3 | Continuing pregnancy after vanishing twin syndrome of one fetus or more, third trimester, fetus 3 |
| O31.43×4 | Continuing pregnancy after vanishing twin syndrome of one fetus or more, third trimester, fetus 4 |
| O31.43×5 | Continuing pregnancy after vanishing twin syndrome of one fetus or more, third trimester, fetus 5 |
| O31.43×0 | Continuing pregnancy after vanishing twin syndrome of one fetus or more, third trimester, not applicable or unspecified |
| O31.43×9 | Continuing pregnancy after vanishing twin syndrome of one fetus or more, third trimester, other fetus |
| O31.40 | Continuing pregnancy after vanishing twin syndrome of one fetus or more, unspecified trimester |
| O31.40×1 | Continuing pregnancy after vanishing twin syndrome of one fetus or more, unspecified trimester, fetus 1 |
| O31.40×2 | Continuing pregnancy after vanishing twin syndrome of one fetus or more, unspecified trimester, fetus 2 |
| O31.40×3 | Continuing pregnancy after vanishing twin syndrome of one fetus or more, unspecified trimester, fetus 3 |
| O31.40×4 | Continuing pregnancy after vanishing twin syndrome of one fetus or more, unspecified trimester, fetus 4 |
| O31.40×5 | Continuing pregnancy after vanishing twin syndrome of one fetus or more, unspecified trimester, fetus 5 |
| O31.40×0 | Continuing pregnancy after vanishing twin syndrome of one fetus or more, unspecified trimester, not applicable or unspecified |
| O31.40×9 | Continuing pregnancy after vanishing twin syndrome of one fetus or more, unspecified trimester, other fetus |
| O00.5 | Cornual ectopic pregnancy |
| O00.52 | Cornual ectopic pregnancy with intrauterine pregnancy |
| O00.51 | Cornual ectopic pregnancy without intrauterine pregnancy |
| I42.00 | Dilated cardiomyopathy, unspecified |
| K6A | Diseases of the pelvis, not elsewhere classified |
| QA1.790 | Familial cancer syndrome with pathogenic BRCA1 mutation |
| QA1.791 | Familial cancer syndrome with pathogenic BRCA2 mutation |
| I42.01 | Familial-genetic dilated cardiomyopathy |
| F64.A | Gender identity disorder, in remission |
| QA1 | Genetic disorders associated with neoplasms, not elsewhere classified |
| D69.11 | Glanzmann thrombasthenia |
| K74.0A | Hepatic fibrosis, moderate fibrosis |
| K31.B | Hypertrophic pyloric stenosis, in childhood |
| QA1.7 | Inherited neoplasm predisposition syndromes involving multiple systems, not elsewhere classified |
| O00.13 | Interstitial ectopic pregnancy with intrauterine pregnancy |
| O00.12 | Interstitial ectopic pregnancy without intrauterine pregnancy |
| K76.83 | Intestinal failure-associated liver disease |
| N99.86 | Intraoperative and postprocedural complications and disorders of breast |
| N99.860 | Intraoperative and postprocedural nipple ischemia |
| N99.861 | Intraoperative and postprocedural nipple necrosis |
| O00.522 | Left cornual ectopic pregnancy with intrauterine pregnancy |
| O00.512 | Left cornual ectopic pregnancy without intrauterine pregnancy |
| O00.132 | Left interstitial ectopic pregnancy with intrauterine pregnancy |
| O00.122 | Left interstitial ectopic pregnancy without intrauterine pregnancy |
| QA1.792 | Li Fraumeni syndrome |
| Q87.A | Loeys-Dietz syndrome |
| QA1.71 | Lynch syndrome |
| J34.83 | Odontogenic sinusitis |
| J34.831 | Odontogenic sinusitis, ethmoid sinus |
| J34.832 | Odontogenic sinusitis, frontal sinus |
| J34.830 | Odontogenic sinusitis, maxillary sinus |
| J34.833 | Odontogenic sinusitis, sphenoid sinus |
| J34.839 | Odontogenic sinusitis, unspecified |
| I42.89 | Other cardiomyopathies not elsewhere classified |
| I42.09 | Other dilated cardiomyopathy |
| K6A.8 | Other diseases of the pelvis, not elsewhere classified |
| QA1.79 | Other inherited neoplasm predisposition syndrome of multiple systems |
| QA1.798 | Other inherited neoplasm predisposition syndrome of multiple systems |
| M86.8×81 | Other osteomyelitis, face and sinuses |
| M86.8×72 | Other osteomyelitis, left ankle and foot |
| M86.8×32 | Other osteomyelitis, left forearm |
| M86.8×42 | Other osteomyelitis, left hand |
| M86.8×62 | Other osteomyelitis, left lower leg |
| M86.8×12 | Other osteomyelitis, left shoulder |
| M86.8×52 | Other osteomyelitis, left thigh |
| M86.8×22 | Other osteomyelitis, left upper arm |
| M86.8×89 | Other osteomyelitis, other site |
| M86.8×71 | Other osteomyelitis, right ankle and foot |
| M86.8×31 | Other osteomyelitis, right forearm |
| M86.8×41 | Other osteomyelitis, right hand |
| M86.8×61 | Other osteomyelitis, right lower leg |
| M86.8×11 | Other osteomyelitis, right shoulder |
| M86.8×51 | Other osteomyelitis, right thigh |
| M86.8×21 | Other osteomyelitis, right upper arm |
| M86.8×80 | Other osteomyelitis, skull |
| M86.8×79 | Other osteomyelitis, unspecified ankle and foot |
| M86.8×39 | Other osteomyelitis, unspecified forearm |
| M86.8×49 | Other osteomyelitis, unspecified hand |
| M86.8×69 | Other osteomyelitis, unspecified lower leg |
| M86.8×19 | Other osteomyelitis, unspecified shoulder |
| M86.8×59 | Other osteomyelitis, unspecified thigh |
| M86.8×29 | Other osteomyelitis, unspecified upper arm |
| K6A.09 | Other pelvic abscess |
| E89.838 | Other postprocedural hypoglycemia |
| D69.19 | Other qualitative platelet defects |
| I49.89 | Other specified cardiac arrhythmias not elsewhere classified |
| K6A.0 | Pelvic abscess |
| Z86.17 | Personal history of Clostridioides difficile infection |
| Z87.893 | Personal history of gender detransition |
| Z87.8904 | Personal history of intersex surgery |
| Z87.8902 | Personal history of medical gender transition |
| Z87.8901 | Personal history of social gender transition |
| Z87.8903 | Personal history of surgical gender transition |
| Z87.8909 | Personal history of unspecified gender transition |
| M72.22 | Plantar fascial fibromatosis, left foot |
| M72.21 | Plantar fascial fibromatosis, right foot |
| M72.20 | Plantar fascial fibromatosis, unspecified foot |
| M67.A | Plantar fasciitis |
| M67.A0 | Plantar fasciitis, foot |
| M67.A02 | Plantar fasciitis, left foot |
| M67.A01 | Plantar fasciitis, right foot |
| M67.A09 | Plantar fasciitis, unspecified foot |
| E89.830 | Post bariatric hypoglycemia |
| E89.83 | Postprocedural hypoglycemia following a procedure |
| K6A.01 | Prevesical abscess |
| J4B | Pulmonary mycetoma |
| O00.521 | Right cornual ectopic pregnancy with intrauterine pregnancy |
| O00.511 | Right cornual ectopic pregnancy without intrauterine pregnancy |
| O00.131 | Right interstitial ectopic pregnancy with intrauterine pregnancy |
| O00.121 | Right interstitial ectopic pregnancy without intrauterine pregnancy |
| C78.31 | Secondary malignant neoplasm of larynx |
| C79.83 | Secondary malignant neoplasm of oral cavity |
| C78.32 | Secondary malignant neoplasm of pharynx |
| T52.811 | Toxic effect of alkenes, accidental (unintentional) |
| T52.811A | Toxic effect of alkenes, accidental (unintentional), initial encounter |
| T52.811S | Toxic effect of alkenes, accidental (unintentional), sequela |
| T52.811D | Toxic effect of alkenes, accidental (unintentional), subsequent encounter |
| T52.813 | Toxic effect of alkenes, assault |
| T52.813A | Toxic effect of alkenes, assault, initial encounter |
| T52.813S | Toxic effect of alkenes, assault, sequela |
| T52.813D | Toxic effect of alkenes, assault, subsequent encounter |
| T52.812 | Toxic effect of alkenes, intentional self-harm |
| T52.812A | Toxic effect of alkenes, intentional self-harm, initial encounter |
| T52.812S | Toxic effect of alkenes, intentional self-harm, sequela |
| T52.812D | Toxic effect of alkenes, intentional self-harm, subsequent encounter |
| T52.814 | Toxic effect of alkenes, undetermined |
| T52.814A | Toxic effect of alkenes, undetermined, initial encounter |
| T52.814S | Toxic effect of alkenes, undetermined, sequela |
| T52.814D | Toxic effect of alkenes, undetermined, subsequent encounter |
| T52.821 | Toxic effect of cycloparaffins, accidental (unintentional) |
| T52.821A | Toxic effect of cycloparaffins, accidental (unintentional), initial encounter |
| T52.821S | Toxic effect of cycloparaffins, accidental (unintentional), sequela |
| T52.821D | Toxic effect of cycloparaffins, accidental (unintentional), subsequent encounter |
| T52.823 | Toxic effect of cycloparaffins, assault |
| T52.823A | Toxic effect of cycloparaffins, assault, initial encounter |
| T52.823S | Toxic effect of cycloparaffins, assault, sequela |
| T52.823D | Toxic effect of cycloparaffins, assault, subsequent encounter |
| T52.822 | Toxic effect of cycloparaffins, intentional self-harm |
| T52.822A | Toxic effect of cycloparaffins, intentional self-harm, initial encounter |
| T52.822S | Toxic effect of cycloparaffins, intentional self-harm, sequela |
| T52.822D | Toxic effect of cycloparaffins, intentional self-harm, subsequent encounter |
| T52.824 | Toxic effect of cycloparaffins, undetermined |
| T52.824A | Toxic effect of cycloparaffins, undetermined, initial encounter |
| T52.824S | Toxic effect of cycloparaffins, undetermined, sequela |
| T52.824D | Toxic effect of cycloparaffins, undetermined, subsequent encounter |
| T59.821 | Toxic effect of hexamethylene diisocyanate, accidental (unintentional) |
| T59.821A | Toxic effect of hexamethylene diisocyanate, accidental (unintentional), initial encounter |
| T59.821S | Toxic effect of hexamethylene diisocyanate, accidental (unintentional), sequela |
| T59.821D | Toxic effect of hexamethylene diisocyanate, accidental (unintentional), subsequent encounter |
| T59.823 | Toxic effect of hexamethylene diisocyanate, assault |
| T59.823A | Toxic effect of hexamethylene diisocyanate, assault, initial encounter |
| T59.823S | Toxic effect of hexamethylene diisocyanate, assault, sequela |
| T59.823D | Toxic effect of hexamethylene diisocyanate, assault, subsequent encounter |
| T59.822 | Toxic effect of hexamethylene diisocyanate, intentional self-harm |
| T59.822A | Toxic effect of hexamethylene diisocyanate, intentional self-harm, initial encounter |
| T59.822S | Toxic effect of hexamethylene diisocyanate, intentional self-harm, sequela |
| T59.822D | Toxic effect of hexamethylene diisocyanate, intentional self-harm, subsequent encounter |
| T59.824 | Toxic effect of hexamethylene diisocyanate, undetermined |
| T59.824A | Toxic effect of hexamethylene diisocyanate, undetermined, initial encounter |
| T59.824S | Toxic effect of hexamethylene diisocyanate, undetermined, sequela |
| T59.824D | Toxic effect of hexamethylene diisocyanate, undetermined, subsequent encounter |
| T65.85 | Toxic effect of medetomidine |
| T65.851 | Toxic effect of medetomidine, accidental (unintentional) |
| T65.851A | Toxic effect of medetomidine, accidental (unintentional), initial encounter |
| T65.851S | Toxic effect of medetomidine, accidental (unintentional), sequela |
| T65.851D | Toxic effect of medetomidine, accidental (unintentional), subsequent encounter |
| T65.853 | Toxic effect of medetomidine, assault |
| T65.853A | Toxic effect of medetomidine, assault, initial encounter |
| T65.853S | Toxic effect of medetomidine, assault, sequela |
| T65.853D | Toxic effect of medetomidine, assault, subsequent encounter |
| T65.852 | Toxic effect of medetomidine, intentional self-harm |
| T65.852A | Toxic effect of medetomidine, intentional self-harm, initial encounter |
| T65.852S | Toxic effect of medetomidine, intentional self-harm, sequela |
| T65.852D | Toxic effect of medetomidine, intentional self-harm, subsequent encounter |
| T65.854 | Toxic effect of medetomidine, undetermined |
| T65.854A | Toxic effect of medetomidine, undetermined, initial encounter |
| T65.854S | Toxic effect of medetomidine, undetermined, sequela |
| T65.854D | Toxic effect of medetomidine, undetermined, subsequent encounter |
| T52.891 | Toxic effect of other organic solvents, accidental (unintentional) |
| T52.891A | Toxic effect of other organic solvents, accidental (unintentional), initial encounter |
| T52.891S | Toxic effect of other organic solvents, accidental (unintentional), sequela |
| T52.891D | Toxic effect of other organic solvents, accidental (unintentional), subsequent encounter |
| T52.893 | Toxic effect of other organic solvents, assault |
| T52.893A | Toxic effect of other organic solvents, assault, initial encounter |
| T52.893S | Toxic effect of other organic solvents, assault, sequela |
| T52.893D | Toxic effect of other organic solvents, assault, subsequent encounter |
| T52.892 | Toxic effect of other organic solvents, intentional self-harm |
| T52.892A | Toxic effect of other organic solvents, intentional self-harm, initial encounter |
| T52.892S | Toxic effect of other organic solvents, intentional self-harm, sequela |
| T52.892D | Toxic effect of other organic solvents, intentional self-harm, subsequent encounter |
| T52.894 | Toxic effect of other organic solvents, undetermined |
| T52.894A | Toxic effect of other organic solvents, undetermined, initial encounter |
| T52.894S | Toxic effect of other organic solvents, undetermined, sequela |
| T52.894D | Toxic effect of other organic solvents, undetermined, subsequent encounter |
| T52.81 | Toxic effects of alkenes |
| T52.82 | Toxic effects of cycloparaffins |
| T59.82 | Toxic effects of hexamethylene diisocyanate |
| T52.89 | Toxic effects of other organic solvents |
| O00.529 | Unspecified cornual ectopic pregnancy with intrauterine pregnancy |
| O00.519 | Unspecified cornual ectopic pregnancy without intrauterine pregnancy |
| O00.139 | Unspecified interstitial ectopic pregnancy with intrauterine pregnancy |
| O00.129 | Unspecified interstitial ectopic pregnancy without intrauterine pregnancy |
| I49.82 | Ventricular bigeminy |
| M04.3 | VEXAS syndrome |
Removals
The following codes and descriptions will be discontinued effective September 30, 2026:
| Code | Description |
| S23.420 | Sprain of sternoclavicular (joint) (ligament) |
| S23.420A | Sprain of sternoclavicular (joint) (ligament), initial encounter |
| S23.420S | Sprain of sternoclavicular (joint) (ligament), sequela |
| S23.420D | Sprain of sternoclavicular (joint) (ligament), subsequent encounter |
| T52.8×1 | Toxic effect of other organic solvents, accidental (unintentional) |
| T52.8x1A | Toxic effect of other organic solvents, accidental (unintentional), initial encounter |
| T52.8x1S | Toxic effect of other organic solvents, accidental (unintentional), sequela |
| T52.8x1D | Toxic effect of other organic solvents, accidental (unintentional), subsequent encounter |
| T52.8×3 | Toxic effect of other organic solvents, assault |
| T52.8x3A | Toxic effect of other organic solvents, assault, initial encounter |
| T52.8x3S | Toxic effect of other organic solvents, assault, sequela |
| T52.8x3D | Toxic effect of other organic solvents, assault, subsequent encounter |
| T52.8×2 | Toxic effect of other organic solvents, intentional self-harm |
| T52.8x2A | Toxic effect of other organic solvents, intentional self-harm, initial encounter |
| T52.8x2S | Toxic effect of other organic solvents, intentional self-harm, sequela |
| T52.8x2D | Toxic effect of other organic solvents, intentional self-harm, subsequent encounter |
| T52.8×4 | Toxic effect of other organic solvents, undetermined |
| T52.8x4A | Toxic effect of other organic solvents, undetermined, initial encounter |
| T52.8x4S | Toxic effect of other organic solvents, undetermined, sequela |
| T52.8x4D | Toxic effect of other organic solvents, undetermined, subsequent encounter |
| T52.8x | Toxic effects of other organic solvents |
Professional Services
Additions
The following codes and descriptions will be effective May 15, 2026:
| Code | Description |
| 87638 | Infectious agent detection by nucleic acid (DNA or RNA); rubeola (measles) virus |
The following codes and descriptions will be effective July 1, 2026:
| Code | Description |
| G0577 | Vascular embolization or occlusion procedure with use of a pressure-generating catheter (e.g., one-way valve, intermittently occluding), inclusive of all radiological supervision and interpretation, intraprocedural roadmapping, and imaging guidance necessary to complete the intervention; for tumors, organ ischemia, or infarction performed in the non-facility setting |
The following codes and descriptions will be effective October 1, 2026:
| Code | Description |
| 0684U | Alcohol use disorder, DNA analysis of 4 methylation markers (cg02583484, cg04987734, cg09935388, cg04583842), methylation-sensitive digital PCR, whole blood, algorithm reported as a summed T-score |
| 0685U | Alcohol use disorder, DNA analysis of 5 methylation markers (4 content: cg02583484, cg04987734, cg09935388, cg04583842, and 1 normalizing: cg08141395), methylation-sensitive digital PCR, whole blood or saliva, algorithm reported as a summed T-score |
| 0692U | Cardiology (peripheral artery disease [PAD]), analysis of 3 proteins (midkine, angiopoietin-1, and kidney injury molecule-1 [KIM-1]), immunoassay, plasma, algorithm reported as a risk score for obstructive PAD |
| 0691U | Carrier screening (cystic fibrosis, spinal muscular atrophy, beta hemoglobinopathies [including sickle cell disease], alpha thalassemia, and Duchenne muscular dystrophy), genomic sequence analysis panel, 6 genes (CFTR, SMN1, HBB, HBA1, HBA2, DMD) |
| 0687U | Comparative analysis using short tandem repeat (STR) markers, patient and comparative specimen, DNA, buccal swab and tissue, reported match or mismatch |
| 0665U | Hepatology (metabolic dysfunction-associated steatohepatitis [MASH]), enzyme-linked immunosorbent assay (ELISA) for YKL40 and quantitative reverse transcription polymerase chain reaction (RT-qPCR) for miR-34a-5p, serum, algorithm reported as a single score for MASH activity and fibrosis |
| 0661U | Human papillomavirus (HPV), genotype 16, cell-free DNA (cfDNA), whole blood, digital droplet PCR (ddPCR), quantitative |
| 0660U | Human papillomavirus (HPV), genotypes 18, 31, 33, and 35, cell-free DNA (cfDNA), whole blood, multiplex digital droplet PCR (ddPCR), quantitative |
| 0667U | Inborn error of metabolism (primary mitochondrial disease), determination of fibroblast growth factor 21 (FGF21) concentration by enzyme-linked immunosorbent assay (ELISA), serum or plasma, diagnostic quantitative result |
| 0669U | Infectious disease (Bartonella species, Borrelia species, and Babesia species), multiplex digital PCR for detection of DNA at the genus level for each species, blood, qualitative reporting of presence or absence of each pathogen at the genus level |
| 0666U | Infectious disease (wound infection), DNA, multiplex real-time PCR, wound swab, detection of 27 microbial targets and 28 antibiotic resistance targets, reported as semiquantitative for bacterial and fungal targets, and qualitative for viral- and antibiotic-resistance targets |
| 0698U | Neurology (traumatic brain injury), analysis of glial fibrillary acidic protein (GFAP) and ubiquitin carboxy-terminal hydrolase L1 (UCHL1), immunoassay, serum or plasma, individual components reported with the overall result of positive or negative based on threshold comparison |
| 0697U | Obesity, DNA genotyping, analysis of up to 41 genes, buccal swab or blood specimen, patient biometrics, risk-score algorithm to identify a predisposition to up to 4 phenotypes, reported as likelihood to benefit from therapeutics |
| 0663U | Obstetrics (fetal platelet antigen noninvasive prenatal test [NIPT]), cell-free DNA (cfDNA) sequence analysis for detection of fetal presence or absence of 1 human platelet antigen or more (HPA-1a, HPA-1b, HPA-3a, HPA-5b, and others) when performed, reported as maternal/fetal incompatibility detected or not detected per selected antigen |
| 0695U | Oncology (central nervous system), low-pass whole genome sequence analysis of cerebrospinal fluid, interrogation for chromosome arm-level and focal losses and gains |
| 0689U | Oncology (colorectal cancer), analysis of minimal residual disease (MRD) using patient-specific assays, reported as amount of circulating tumor DNA (ctDNA) detection and trend over time |
| 0688U | Oncology (colorectal cancer), analysis of minimal residual disease (MRD), next-generation sequencing (NGS), circulating tumor DNA (ctDNA) analysis in whole blood and tumor for baseline assessment to evaluate current MRD status and for comparisons to subsequent MRD assessments |
| 0693U | Oncology (head and neck), circulating tumor DNA (ctDNA), tumor-informed next-generation sequencing (NGS) analysis for 699 genes of patient-specific somatic variants identified from primary tumor tissue, postoperative lymphatic exudate specimen, algorithm reported as presence or absence of ctDNA |
| 0678U | Oncology (hereditary cancer), genome sequence for 117 genes (single-nucleotide variants, deletions/insertions, and characterized intronic variants), copy number variants, duplications/deletions, mobile element insertions and inversions, blood, saliva, cultured skin fibroblasts (skin biopsy) or extracted genomic DNA, diagnostic, identification and categorization of genetic variants |
| 0679U | Oncology (hereditary hematologic cancer), genomic DNA, whole genome sequence (single-nucleotide variants, deletions/insertions, and characterized intronic variants), copy number variants, duplications/deletions, mobile element insertions and inversions, analysis of over 105 genes, genomic DNA isolated from blood, saliva, cultured skin fibroblasts (skin biopsy), identification and categorization of genetic variants |
| 0682U | Oncology (lung cancer), DNA analysis of 1 methylation marker (cg05575921), methylation-sensitive digital PCR, whole blood, algorithm results reported as the 20-year-hazard ratio for lung cancer |
| 0683U | Oncology (lung cancer), DNA analysis of 2 methylation markers (1 content: cg05575921 and 1 normalizing: cg08141395), methylation-sensitive digital PCR, saliva, algorithm results reported as the 20-year-hazard ratio for lung cancer |
| 0694U | Oncology (monoclonal gammopathy), immunoprecipitation and matrix-assisted laser desorption/ionization time-of-flight (MALDI-TOF) mass spectrometry, identification of intact monoclonal immunoglobulin isotypes (IgG, IgA, IgM, kappa, lambda), and M-protein concentrations in conjunction with turbidimetry, blood, semiquantitative |
| 0668U | Oncology (pancreas), DNA, genome sequence with 5-hydroxymethylcytosine (5hmC) enrichment and glycan biomarker analysis, whole blood or plasma, algorithm reported as cancer detected or not detected |
| 0686U | Oncology (prostate), mRNA, next-generation sequencing (NGS) gene expression profiling of 22 genes, formalin-fixed paraffin-embedded (FFPE) tissue, algorithm reported as risk score |
| 0696U | Oncology (solid organ), targeted genomic sequence analysis, formalin-fixed paraffin-embedded (FFPE) tumor tissue, RNA analysis, 350 or more genes for RNA alterations (e.g. gene rearrangements and splice isoforms) |
| 0673U | Rare diseases (constitutional/heritable disorders), whole exome and mitochondrial DNA sequence analysis, including small sequence changes, deletions, duplications, short tandem repeat (STR) gene expansions, and variants in nonuniquely mappable regions, blood or saliva, identification and categorization of genetic variants, proband and 2 comparators |
| 0672U | Rare diseases (constitutional/heritable disorders), whole exome and mitochondrial DNA sequence analysis, including small sequence changes, deletions, duplications, short tandem repeat (STR) gene expansions, and variants in nonuniquely mappable regions, blood or saliva, identification and categorization of genetic variants, proband and comparator |
| 0675U | Rare diseases (constitutional/heritable disorders), whole genome and mitochondrial DNA sequence analysis, including small sequence changes, insertions/deletions, copy number variants, duplications/deletions, mobile element insertions, runs of homozygosity, aneuploidy, and inversions, short tandem repeat (STR) gene expansions, blood, saliva, or genomic DNA, identification and categorization of genetic variants proband and 2 comparators |
| 0674U | Rare diseases (constitutional/heritable disorders), whole genome and mitochondrial DNA sequence analysis, including small sequence changes, insertions/deletions, copy number variants, mobile element insertions, runs of homozygosity, aneuploidy, and inversions, short tandem repeat (STR) gene expansions, blood, saliva, or genomic DNA, identification and categorization of genetic variants, proband and comparator |
| 0670U | Rare diseases (constitutional/heritable disorders), whole genome sequence analysis combination of short and long reads for single-nucleotide variants, insertions/deletions and characterized intronic variants, copy number variants, duplications/deletions, mobile element insertions, runs of homozygosity, aneuploidy, and inversions, mitochondrial DNA sequence and deletions, short tandem repeat (STR) genes, methylation status of selected regions, blood, saliva, amniocentesis, chorionic villus sample or tissue, identification and categorization of genetic variant, proband and comparator |
| 0671U | Rare diseases (constitutional/heritable disorders), whole genome sequence analysis combination of short and long reads for single-nucleotide variants, insertions/deletions and characterized intronic variants, copy number variants, duplications/deletions, mobile element insertions, runs of homozygosity, aneuploidy, and inversions, mitochondrial DNA sequence and deletions, short tandem repeat (STR) genes, methylation status of selected regions, blood, saliva, amniocentesis, chorionic villus sample or tissue, identification and categorization of genetic variant, proband and 2 comparators |
| 0676U | Rare diseases (constitutional/heritable disorders), whole genome sequence analysis, including small sequence changes, copy number variants, deletions, duplications, mobile element insertions, uniparental disomy (UPD), inversions, aneuploidy, mitochondrial genome sequence analysis with heteroplasmy and large deletions, short tandem repeat (STR) gene expansions and maternal cell contamination, fetal sample, identification and categorization of genetic variants, proband and maternal comparator |
| 0677U | Rare diseases (constitutional/heritable disorders), whole genome sequence analysis, including small sequence changes, copy number variants, deletions, duplications, mobile element insertions, uniparental disomy (UPD), inversions, aneuploidy, mitochondrial genome sequence analysis with heteroplasmy and large deletions, short tandem repeat (STR) gene expansions and maternal cell contamination, fetal sample, identification and categorization of genetic variants, proband and 2 comparators |
| 0680U | Tobacco use, DNA analysis of 1 methylation marker (cg05575921 [AHRR]), methylation-sensitive digital PCR, whole blood, algorithm reported as quantitative percentage methylation and estimated average cigarette use per day |
| 0681U | Tobacco use, DNA analysis of 2 methylation markers (1 content: cg05575921 [AHRR] and 1 normalizing: cg08141395), methylation-sensitive digital PCR, saliva, algorithm reported as quantitative percent methylation and estimated average cigarette use per day |
| 0690U | Transplantation medicine (allograft rejection), quantification of donor-derived cell-free DNA (cfDNA) using digital PCR analysis of 45 single-nucleotide polymorphisms, plasma, reported as quantity of donor-derived cfDNA in plasma to determine the probability of allograft rejection |
| 0664U | Transplantation medicine (kidney allograft failure), RNA expression transcriptome by next-generation sequencing (NGS), profiling of 13 genes, post-transplant peripheral blood, algorithm reported as a risk score for predicting progressive fibrosis in the kidney allograft |
| 0662U | Transplantation medicine (kidney allograft rejection), mRNA, gene-expression profiling by real-time quantitative PCR of 12 genes (11 content and 1 housekeeping), urine, algorithm reported as a rejection risk score |
The following descriptions and codes will be effective January 1, 2027:
| Code | Description |
| 1079T | 3D quantitative transmission water bath volumetric ultrasound tomography, breast, with augmentative algorithmic derivation of breast tissue composition (i.e., fibroglandular volume), bilateral, with physician or other qualified health care professional interpretation and report |
| 1099T | Ablation of incompetent vein(s), extremity, transcutaneous, high intensity-focused ultrasound (HIFU), inclusive of all imaging guidance and monitoring |
| 1062T | Artificial insemination, transcervical intratubal, unilateral or bilateral, including imaging guidance |
| 1085T | Assistive algorithmic analysis for identification of new lesions and determination of inter-lesion heterogeneity of change in metabolic activity and volume for advanced metastatic cancer, data sets from 2 or more previously acquired positron emission tomography (PET) and/or PET computed tomography (CT) (PET/CT) studies |
| 1090T | Attachment and insertion of intraocular lens prosthesis-mounted drug-eluting implant (List separately in addition to code for primary procedure) |
| 1056T | Cochlear infusion of pharmacologic agent (i.e., gene therapy vector), including mastoidectomy, labyrinthotomy, and repair of fenestrations |
| 1068T | Cystourethroscopy, with CO2 cryotherapy spray, in a gaseous bladder environment with pressure monitoring, for treatment of; large bladder lesion(s) (total lesion[s] diameters greater than or equal to 5.0 cm) |
| 1067T | Cystourethroscopy, with CO2 cryotherapy spray, in a gaseous bladder environment with pressure monitoring, for treatment of; medium bladder lesion(s) (total lesion[s] diameters greater than or equal to 2.0 cm and less than 5.0 cm) |
| 1065T | Cystourethroscopy, with CO2 cryotherapy spray, in a gaseous bladder environment with pressure monitoring, for treatment of; minor bladder lesion(s) (total lesion[s] diameters less than 0.5 cm) |
| 1066T | Cystourethroscopy, with CO2 cryotherapy spray, in a gaseous bladder environment with pressure monitoring, for treatment of; small bladder lesion(s) (total lesion[s] diameters greater than or equal to 0.5 cm and less than 2.0 cm) |
| 1060T | Electronic analysis of implanted subcutaneous supraorbital-occipital neurostimulator pulse generator (e.g. frequency, amplitude, pulse width, leads, electrode configuration); with complex programming by physician or other qualified health care professional |
| 1061T | Electronic analysis of implanted subcutaneous supraorbital-occipital neurostimulator pulse generator (e.g. frequency, amplitude, pulse width, leads, electrode configuration); with simple programming by physician or other qualified health care professional |
| 1087T | Estimate of coronary fractional flow derived by augmentative algorithmic analysis of data from previously acquired coronary angiogram, with creation of functional map of coronary circulation, when performed, with automated result |
| 1054T | Focused non-shock wave ultrasonic propulsion of residual stone fragment(s) post-lithotripsy, unilateral, including ultrasound guidance, fragment(s) less than or equal to 5 mm |
| 1095T | Harvesting and processing of autologous bone marrow aspirate concentrate (BMAC), with application onto scaffold or injection into anatomical recipient site (e.g. subchondral bone, joint space, chondral lesion), including imaging guidance, when performed, for therapeutic musculoskeletal treatment, excluding spinal procedures |
| 1094T | Implantation of acellular scaffold (e.g. hyaluronan), knee, single implant; each additional acellular scaffold implantation (List separately in addition to code for primary procedure) |
| 1093T | Implantation of acellular scaffold (e.g. hyaluronan), knee, single implant; into a chondral or osteochondral defect, arthroscopic |
| 1092T | Implantation of acellular scaffold (e.g. hyaluronan), knee, single implant; into chondral defect, open |
| 1084T | Implantation of scaffolding allograft to reinforce the suprachoroidal space |
| 1096T | Injection(s) of thermoregulated multiphase suspension to demyelinate nerves innervating the knee joint, including imaging guidance, when performed |
| 1057T | Insertion or replacement of subcutaneous neurostimulator pulse generators, with tunneling of 4 electrode arrays, bilateral supraorbital and occipital nerves, including all interrogation, programming, and imaging guidance, when performed |
| 1080T | Insertion, intracapsular magnifier, with attachment to previously placed intraocular lens |
| 1102T | Intraoperative molecular assessment for lung tumor tissue, in-vivo (including assessment, when performed following lung resection), using computer-aided fluorescence imaging (List separately in addition to code for primary procedure) |
| 1103T | Intraoperative molecular assessment for ovarian, tubal, or peritoneal tumor tissue, in-vivo (including assessment, when performed following ovarian, tubal, or peritoneal resection), using computer-aided fluorescence imaging (List separately in addition to code for primary procedure) |
| 1089T | Intraoperative quantitative micro-elastography tissue characterization, including real-time imaging and physician assessment, per breast |
| 1055T | Intraoperative radiofrequency ablation of lumpectomy cavity, unilateral, including applicator placement and removal (List separately in addition to code for primary procedure) |
| 1086T | Intraprocedural estimate of coronary fractional flow derived by augmentative algorithmic analysis of data from real-time coronary angiography, with creation of functional map of coronary circulation, when performed, with review and interpretation (List separately in addition to code for primary procedure) |
| 1074T | Liver allograft, hypothermic oxygenated perfusion; cannulation |
| 1075T | Liver allograft, hypothermic oxygenated perfusion; connection to perfusion device |
| 1078T | Liver allograft, hypothermic oxygenated perfusion; decannulation |
| 1077T | Liver allograft, hypothermic oxygenated perfusion; each additional hour of monitoring and management (List separately in addition to code for primary procedure) |
| 1076T | Liver allograft, hypothermic oxygenated perfusion; monitoring and management, first 2 hours |
| 1073T | Liver allograft, normothermic machine perfusion; decannulation |
| 1072T | Liver allograft, normothermic machine perfusion; each additional hour of monitoring and management (List separately in addition to code for primary procedure) |
| 1070T | Mechanical extremity (i.e., hands and feet) cryocompression; individual glove and boot placement, initiation of cooling pre-chemotherapy and continuing through chemotherapy administration |
| 1069T | Mechanical extremity (i.e., hands and feet) cryocompression; individual glove and boot supplies with initial measurement, fitting, and therapy education |
| 1071T | Mechanical extremity (i.e., hands and feet) cryocompression; post-chemotherapy treatment continuation, each 30 minutes (List separately in addition to code for primary procedure) |
| 1082T | Microvascular anastomosis between a lymph node and a vein, including robot assistance, when performed; each additional anastomosis (List separately in addition to code for primary procedure) |
| 1081T | Microvascular anastomosis between a lymph node and a vein, including robot assistance, when performed; initial anastomosis |
| 1104T | Noninvasive cardiopulmonary assessment, including quantitative parameters, respectively predictive of significant epicardial coronary artery disease, pulmonary hypertension, and/or elevated pulmonary capillary wedge pressure, derived by augmentative algorithmic analysis of orthogonal voltage gradient and photoplethysmography signals, with automated report |
| 1063T | Oncology (bladder), augmentative algorithmic analysis of histomorphologic features in digitized slides from formalin-fixed paraffin-embedded (FFPE) bladder cancer tissue (high-grade, non-muscle invasive), with clinicopathologic variables entered by the qualified health care professional; algorithm-derived parameters reported as prognostic of recurrence and progression, including hematoxylin and eosin staining of tissue sections, and digitization of glass microscope slides, when performed |
| 1064T | Oncology (bladder), augmentative algorithmic analysis of histomorphologic features in digitized slides from formalin-fixed paraffin-embedded (FFPE) bladder cancer tissue (high-grade, non-muscle invasive), with clinicopathologic variables entered by the qualified health care professional; algorithm-derived parameters reported as predictive of response to Bacillus Calmette-Guérin (BCG) therapy, including hematoxylin and eosin staining of tissue sections, and digitization of glass microscope slides, when performed |
| 1106T | Oncology (breast), augmentative algorithmic analysis of histomorphologic features in digitized hematoxylin and eosin stained slides from formalin-fixed paraffin-embedded (FFPE) breast cancer tissue, algorithm-derived parameters reported as 5-year and 10-year risks of distant metastasis, including digitization of glass microscope slides and hematoxylin and eosin staining of tissue sections, when performed |
| 1097T | Oncology (pancreas), augmentative algorithmic analysis of histomorphologic features in digitized slides from formalin-fixed paraffin-embedded pancreatic cancer tissue, algorithm-derived parameters reported as prediction of response to fluorouracil backbone versus gemcitabine backbone chemotherapy, including hematoxylin and eosin staining of tissue sections and digitization of glass microscope slides, when performed |
| 1107T | Oncology (prostate), augmentative algorithmic analysis of histomorphologic features in digitized hematoxylin and eosin stained slide(s) from formalin-fixed paraffin-embedded (FFPE) prostate cancer tissue, algorithm-derived parameters reported as 10-year risk of distant metastasis and prostate cancer specific mortality, including hematoxylin and eosin staining of tissue sections, and digitization of glass microscope slides, when performed |
| 1088T | Percutaneous application of high-frequency neuromodulation signals using microneedle electrode array for the treatment of nociceptive or neuropathic pain, including electrode placement and patient training, per day |
| 1105T | Personalized neurostimulation pulse rate derived by augmentative algorithmic analysis of data from electroencephalogram (EEG) and electrocardiogram (ECG), including acquisition of EEG and single-lead ECG, with automated report |
| 1091T | Placement of permanent common carotid artery filter, percutaneous, bilateral, including ultrasound guidance, when performed |
| 1098T | Placement of subretinal prosthesis, including vitrectomy |
| 1059T | Removal of implanted subcutaneous unilateral supraorbital and occipital neurostimulator system |
| 1058T | Revision of implanted subcutaneous unilateral supraorbital and occipital neurostimulator system, including all interrogation, programming, and imaging guidance, when performed |
| 1111T | Stereotactic intracerebral delivery of therapeutic agent, by controlled infusion, unilateral, including cranial access and intraoperative imaging guidance, when performed; multiple trajectories |
| 1110T | Stereotactic intracerebral delivery of therapeutic agent, by controlled infusion, unilateral, including cranial access and intraoperative imaging guidance, when performed; single trajectory |
| 1108T | Stereotactic intracerebral implantation of therapeutic agent, unilateral, including cranial access and intraoperative imaging guidance, when performed; 1 or more injections along a single trajectory |
| 1109T | Stereotactic intracerebral implantation of therapeutic agent, unilateral, including cranial access and intraoperative imaging guidance, when performed; 1 or more injections along multiple trajectories |
| 1083T | Stereotactic placement of infusion catheter(s), brain, for delivery of therapeutic agent(s), including computerized stereotactic planning and burr hole(s) |
| 1101T | Transcutaneous spinal neuromodulation application in combination with therapeutic activities, direct (one-on-one) patient contact using dynamic activities to improve functional performance, including individualized external placement of a multichannel spinal electrode pad, optimization of stimulation parameters across multiple channels, and delivery of transcutaneous spinal neuromodulation during functional task performance, each 15 minutes |
| 1100T | Transcutaneous spinal neuromodulation programming, including history and physical examination, safety screening, selection and external placement of a multichannel spinal electrode pad, baseline spinal motor mapping, creation of individualized stimulation parameter sets for therapeutic activities, and patient and/or caregiver instruction, each 30 minutes |
Removals
The following descriptions and codes will be discontinued effective September 30, 2026:
| Code | Description |
| 0556U | Infectious disease (bacterial or viral respiratory tract infection), pathogen-specific DNA and RNA by real-time PCR, 12 targets, nasopharyngeal or oropharyngeal swab, including multiplex reverse transcription for RNA targets, each analyte reported as detected or not detected |
| 0557U | Infectious disease (bacterial vaginosis and vaginitis), real-time amplification of DNA markers for Atopobium vaginae, Gardnerella vaginalis, Megasphaera types 1 and 2, bacterial vaginosis associated bacteria-2 and -3 (BVAB-2, BVAB-3), Mobiluncus species, Trichomonas vaginalis, Neisseria gonorrhoeae, Candida species (C. albicans, C. tropicalis, C. parapsilosis, C. glabrata, C. krusei), Herpes simplex viruses 1 and 2, vaginal fluid, reported as detected or not detected for each organism |
| 0585U | Targeted genomic sequence analysis panel, solid organ neoplasm, circulating cell-free DNA (cfDNA) analysis from plasma of 521 genes, interrogation for sequence variants, gene copy number amplifications, gene rearrangements, and microsatellite instability, report shows identified mutations, including variants with clinical actionability |
Problem Groups
Additions
- Large B-Cell Lymphoma: Updated the Curbside Connect inference link within this problem group.
Updates
The following problems were added to the following problem groups with the following membership rules:
| Problem | Problem Group | Include | Include children |
| Immunoglobulin G4 related disease | Autoimmune, Other | Yes | No |
Problems (SNOMED)
Removals
The standard body has retired the following concepts. Where applicable, a replacement concept has been provided:
| Retired SNOMED Concept Description | Replaced by Description |
| 1958 | N/A |
| 1974 | N/A |
| 1978 | N/A |
| 1982 | N/A |
| 1987 | N/A |
| 1992 | N/A |
| 1997 | N/A |
| 150 milligram calcium diet | N/A |
| 200 milligram calcium diet | N/A |
| 4-nitrobiphenyl | N/A |
| Abdominal stoma | N/A |
| Abnormal extracardiac tracer uptake | N/A |
| Abnormal findings diagnostic imaging heart+coronary circulat | N/A |
| Abnormal findings diagnostic imaging of liver+biliary tract | N/A |
| Abnormal findings on diagnostic imaging of breast | Imaging of breast abnormal |
| Abnormal findings on diagnostic imaging of limbs | N/A |
| Abnormal findings on diagnostic imaging of lung | Imaging of lung abnormal |
| Abnormal findings on diagnostic imaging of skull and head | Imaging of head abnormal |
| Abnormal findings on diagnostic imaging of urinary organs | Imaging of urinary system abnormal |
| Accidental poisoning by mercury and/or mercury compound and/or mercury vapor | Accidental poisoning caused by mercury and/or mercury compound |
| Accidental poisoning by mercury compounds | Accidental poisoning caused by mercury compound |
| Accidental poisoning by mercury vapor | Accidental poisoning caused by mercury vapor |
| Accidental poisoning by nickel compounds | Accidental poisoning caused by nickel compound |
| Accidental poisoning by thallium compounds | Accidental poisoning caused by thallium compound |
| Accidental poisoning from exhaust gas of moving motor vehicle on road | Accidental poisoning by motor vehicle exhaust gas |
| Acne keloidalis | N/A |
| Actinomadura glauciflava | N/A |
| Active healthcare will | N/A |
| Acute dystonia caused by antipsychotic medication | N/A |
| Acute inferior non-ST segment elevation myocardial infarction of right ventricle | Acute non-ST segment elevation myocardial infarction of inferior wall involving right ventricle |
| Acute interstitial pneumonitis | Idiopathic diffuse alveolar damage |
| Acute miliary tuberculosis of multiple sites | Acute miliary tuberculosis |
| Acute miliary tuberculosis of single site | Acute miliary tuberculosis |
| Acute splenic tumor | N/A |
| Adult gender identity disorder, sexually attracted to both sexes | N/A |
| Adult gender identity disorder, sexually attracted to females | N/A |
| Adult gender identity disorder, sexually attracted to males | N/A |
| Adult gender identity disorder, sexually attracted to neither sex | N/A |
| Advance directive discussed with patient | Advance healthcare directive discussed with patient |
| Advance directive discussed with relative | Advance healthcare directive discussed with family member |
| Alcoholic macrocytosis | N/A |
| Allergenic extract | Allergen extract |
| Alopecia, epilepsy, intellectual disability syndrome Moynahan type | Perniola Krajewska Carnevale syndrome |
| Aluminum hydroxide hydrate | N/A |
| Amnestic disorder caused by volatile solvent | Amnestic disorder caused by volatile inhalant |
| Amphotericin B lipid complex | N/A |
| Amphotericin B lipid complex 5 mg/mL solution for injection | N/A |
| Amphotericin B lipid complex only product | N/A |
| Amphotericin B lipid complex only product in parenteral dose form | N/A |
| Anemia in end stage renal disease | Anemia in chronic kidney disease stage 5 |
| Anesthetic face mask | N/A |
| Aneurysmectomy with anastomosis | N/A |
| Aneurysmectomy with anastomosis of abdominal artery | N/A |
| Aneurysmectomy with anastomosis of abdominal vein | N/A |
| Aneurysmectomy with anastomosis of head and neck artery | N/A |
| Aneurysmectomy with anastomosis of lower limb artery | N/A |
| Aneurysmectomy with anastomosis of lower limb vein | N/A |
| Aneurysmectomy with anastomosis of thoracic artery | N/A |
| Aneurysmectomy with anastomosis of upper limb artery | N/A |
| Angiocardiography awaited | N/A |
| Angiography of cervicocerebral arteries | N/A |
| Angio-osteohypertrophic syndrome | N/A |
| Angioosteohypotrophic syndrome | Congenital phlebectasia |
| Anodal closure clonus | N/A |
| Anodal opening clonus | N/A |
| Antenatal amniocentesis – awaited | N/A |
| Antenatal ultrasound scan abnormal | N/A |
| Antenatal ultrasound scan awaited | N/A |
| Anterior slant | N/A |
| Anterior subcapsular lens opacities | N/A |
| Apolipoprotein A-I deficiency | N/A |
| Artery specimen | N/A |
| Asclepiadaceae poisoning | Poisoning caused by Apocynaceae |
| Asterotoxin | N/A |
| Attention – action | N/A |
| Attention to anastomosis | N/A |
| Attention to arteriovenous shunt | N/A |
| Attention to artificial voice box in larynx | N/A |
| Attention to catheter | N/A |
| Attention to cemented hybrid prosthetic replacement of knee joint | N/A |
| Attention to central venous catheter | N/A |
| Attention to cerebroventricular shunt | N/A |
| Attention to cochlear prosthesis | N/A |
| Attention to colonic tube | N/A |
| Attention to colostomy | N/A |
| Attention to component of connection from ventricle of brain | N/A |
| Attention to connection of esophagus | N/A |
| Attention to connection of ileum | N/A |
| Attention to device | N/A |
| Attention to drainage of urinary bladder | N/A |
| Attention to dressing of burn of head or neck | N/A |
| Attention to dressing of burnt skin | N/A |
| Attention to dressing of skin | N/A |
| Attention to dressing of skin of head | N/A |
| Attention to dressing of skin of neck | N/A |
| Attention to duodenostomy | N/A |
| Attention to electromagnetic stimulator in bone | N/A |
| Attention to endoprosthesis of bone | N/A |
| Attention to feeding tube | N/A |
| Attention to flatus tube | N/A |
| Attention to gastric balloon | N/A |
| Attention to gastrointestinal tract tube | N/A |
| Attention to gastrostomy | N/A |
| Attention to gastrostomy tube | N/A |
| Attention to hearing aid | N/A |
| Attention to hearing implant in external ear | N/A |
| Attention to hearing implant in middle ear | N/A |
| Attention to heel protector | N/A |
| Attention to hybrid prosthetic replacement of shoulder joint using cement | N/A |
| Attention to hybrid total knee replacement | N/A |
| Attention to ileostomy | N/A |
| Attention to implanted drug delivery system | N/A |
| Attention to intracranial pressure catheter | N/A |
| Attention to intracranial pressure measuring device | N/A |
| Attention to intracranial pressure transducer | N/A |
| Attention to intrathecal drug delivery device adjacent to spinal cord | N/A |
| Attention to jejunostomy | N/A |
| Attention to laryngeal prosthetic device | N/A |
| Attention to middle ear ventilation tube | N/A |
| Attention to nasoduodenal tube | N/A |
| Attention to naso-esophageal tube | N/A |
| Attention to nasogastric tube | N/A |
| Attention to nasojejunal tube | N/A |
| Attention to nephrostomy tube | N/A |
| Attention to neurostimulator adjacent to spinal cord | N/A |
| Attention to orogastric tube | N/A |
| Attention to penile prosthesis | N/A |
| Attention to percutaneously inserted tubal prosthesis in bile duct | N/A |
| Attention to peritoneal drain | N/A |
| Attention to plaster cast | N/A |
| Attention to prosthesis for limb | N/A |
| Attention to prosthesis of aorta | N/A |
| Attention to prosthesis within duodenum | N/A |
| Attention to prosthesis within esophagus | N/A |
| Attention to prosthesis within large intestine | N/A |
| Attention to prosthesis within small intestine | N/A |
| Attention to prosthesis within stomach | N/A |
| Attention to prosthetic ear bone anchor pin | N/A |
| Attention to prosthetic replacement of articulation of bone | N/A |
| Attention to prosthetic replacement of head of humerus | N/A |
| Attention to skin creases | N/A |
| Attention to skin expander in subcutaneous tissue | N/A |
| Attention to stoma | N/A |
| Attention to total hip replacement | N/A |
| Attention to total knee replacement | N/A |
| Attention to total prosthetic replacement of elbow joint | N/A |
| Attention to total prosthetic replacement of shoulder joint | N/A |
| Attention to tracheostomy | N/A |
| Attention to urinary catheter | N/A |
| Attention to ventriculoperitoneal shunt | N/A |
| Attention to ventriculopleural shunt | N/A |
| Atypical (pseudosarcomatous) histiocytoma of skin | N/A |
| Auditory reflex | N/A |
| Auditory/vestibular test abnormal | N/A |
| Awaiting admission elsewhere | N/A |
| Awaiting corneal transplant | N/A |
| Awaiting hospital death discharge letter | N/A |
| Awaiting radiotherapy | N/A |
| Awaiting request | N/A |
| Awaiting transplantation | N/A |
| Awaiting transplantation of bone marrow | N/A |
| Awaiting transplantation of heart | N/A |
| Awaiting transplantation of kidney | N/A |
| Awaiting transplantation of kidney and pancreas | N/A |
| Awaiting transplantation of liver | N/A |
| Awaiting transplantation of lung | N/A |
| Babesia EU1 | N/A |
| Bacillus subtilis subtilis | Bacillus subtilis |
| Bard-Pic syndrome | Obstruction of bile duct due to malignant neoplasm of head of pancreas |
| Benign concentric annular macular dystrophy | Retinitis pigmentosa |
| Benign infantile focal epilepsy with midline spikes and waves during sleep | Self-limited familial infantile epilepsy |
| Benign occipital lobe epilepsy | N/A |
| Besnier’s prurigo | N/A |
| Biopsy of cervix with fulguration | N/A |
| Blastoschizomyces | Magnusiomyces |
| Bleeding diathesis due to thromboxane synthesis deficiency | N/A |
| Blood product unit awaiting inspection and entry to inventory | N/A |
| Body fluid property | Observable entity |
| Body product observable | Observable entity |
| Bone dysplasia lethal Holmgren type | Desbuquois syndrome |
| Bouchard’s disease | Dilatation of stomach |
| Bouin fluid | Bouin fluid |
| Bragard’s sign | N/A |
| Bronchography abnormal | N/A |
| Bronchography normal | N/A |
| Calcification cluster | Grouped calcification distribution |
| Calcinosis within skin cyst or tumor | N/A |
| Calendar year | N/A |
| Candida krusei DNA | N/A |
| Candidal perionyxis | N/A |
| Cardioassist | N/A |
| Cardiology domiciliary visit done | N/A |
| Cardiology domiciliary visit requested | N/A |
| Carnoy fixative | Carnoy fixative |
| Carotid A angiogram normal | Angiography of carotid artery normal |
| Cathodal closure clonus | N/A |
| Cathodal opening clonus | N/A |
| Cedar oil | N/A |
| Cerebellar lenticular nucleus | Lentiform nucleus structure |
| Chagas’ disease with other organ involvement | Infection by Trypanosoma cruzi |
| Chewing exercises | N/A |
| Choreoacanthocytosis | N/A |
| Chronic miliary tuberculosis | Miliary tuberculosis |
| Citrullinemia, neonatal type | N/A |
| Class Ascomycetes | Ascomycota |
| Cleft lip retinopathy syndrome | N/A |
| Clemastine (as clemastine fumarate hydrochloride) 1 mg oral tablet | Clemastine-containing product in oral dose form |
| Clemastine fumarate hydrochloride | Clemastine fumarate |
| Coccygeal muscle | N/A |
| Colonoscopic control of bleeding | N/A |
| Combination internal cardiac defibrillator and pacemaker in situ | N/A |
| Complicated diaphragmatic hernia | N/A |
| Complicated femoral hernia | N/A |
| Congenital systemic arteriovenous fistula | Congenital arteriovenous fistula |
| Congenital zonular cataract | N/A |
| Congestive heart failure stage B | Stage B at high risk of heart failure |
| Congestive heart failure stage B due to ischemic cardiomyopathy | Stage B at high risk of systolic heart failure due to ischemic cardiomyopathy |
| Construction of abdominal stoma | Stoma |
| Construction of cecostomy | N/A |
| Construction of external stoma | Stoma |
| Construction of stoma of thorax | Stoma |
| Contrast media seen in plaque | N/A |
| Coronary arteriography awaited | N/A |
| Coronary perfusion catheter | N/A |
| Coroner report – paid for | N/A |
| Coroner report – requested | N/A |
| Coroner report – sent off | N/A |
| Coroner’s postmortem report awaited | N/A |
| Coroner’s postmortem report received | N/A |
| Coroner’s postmortem report requested | N/A |
| Coroner’s postmortem report status | N/A |
| Coroner’s report status | N/A |
| Cortical lens opacities | N/A |
| Corynebacterium mediolanum | Agromyces mediolanus |
| Corynebacterium tenuis | Corynebacterium flavescens |
| Craniometaphyseal dysplasia – mild type | N/A |
| Craniometaphyseal dysplasia – severe type | N/A |
| Creation of ileostomy | Ileostomy |
| Creation of jejunostomy | Jejunostomy |
| Cryptococcus uniguttulatus | N/A |
| CT follow-up | N/A |
| Cytokine release syndrome | Cytokine storm syndrome |
| Delphian lymphadenopathy | N/A |
| Dental caries secondary to acquired defects of tooth structure | Dental caries following acquired defect of tooth structure |
| Dental caries secondary to developmental defects of tooth structure | Dental caries following developmental defect of tooth structure |
| Dermatitis vegetans | N/A |
| Dermatology domiciliary visit done | N/A |
| Dermatology domiciliary visit requested | N/A |
| Desquamative interstitial pneumonitis | Alveolar macrophage pneumonia |
| Deventer’s pelvis | Platypelloid pelvis |
| Diabetes mellitus associated with hormonal etiology | N/A |
| Diabetes mellitus caused by insulin receptor antibodies | N/A |
| Diabetology domiciliary visit done | N/A |
| Diabetology domiciliary visit requested | N/A |
| Diastolic heart failure stage B | Stage B at high risk of diastolic heart failure |
| Dibasic sodium phosphate dihydrate | N/A |
| Dibasic sodium phosphate heptahydrate | N/A |
| Diethyl methacrylate | N/A |
| Diethyl methacrylate only product | N/A |
| Diethyl methacrylate-containing product | N/A |
| Diffuse spasm of esophagus | Distal esophageal spasm |
| Digit span forwards | N/A |
| Digit span reverse | N/A |
| Diphyllobothrium houghtonii | Spirometra mansoni |
| Diphyllobothrium minus | N/A |
| Diphyllobothrium strictum | Dicrocoelium dendriticum |
| Diphyllobothrium yonagoensis | Diphyllobothrium stemmacephalum |
| Disabled driver report requested | N/A |
| Disabled driver report status | N/A |
| Disabled registration report requested | N/A |
| Disabled registration report status | N/A |
| Discontinued pesticide | N/A |
| Disseminated pneumocystosis | Disseminated infection caused by Pneumocystis jirovecii |
| Domiciliary visit received | N/A |
| Domiciliary visit requested | N/A |
| Domiciliary visit status | N/A |
| Driver license fitness report status | N/A |
| Drug-induced | N/A |
| Dyspnea, class I | N/A |
| Dyspnea, class II | N/A |
| Dyspnea, class III | N/A |
| Dyspnea, class IV | N/A |
| Early postpartum state | N/A |
| Ebstein-like malformation of mitral valve | N/A |
| Ebstein’s anomaly of common atrioventricular valve | N/A |
| Ebstein’s anomaly of left atrioventricular valve | N/A |
| Elastic band truss umbilical, single belt right | N/A |
| Elephantiasic | N/A |
| Employment report status | N/A |
| End organ deafness | Sensorineural hearing loss |
| End stage renal disease due to benign hypertension | Chronic kidney disease stage 5 due to benign hypertension |
| End stage renal disease due to hypertension | Chronic kidney disease stage 5 due to hypertension |
| End stage renal disease on dialysis due to drug induced diabetes mellitus | Chronic kidney disease stage 5 on dialysis due to drug induced diabetes mellitus |
| End stage renal disease on dialysis due to hypertension | Chronic kidney disease stage 5 due to hypertension on dialysis |
| End stage renal disease on dialysis due to type 1 diabetes mellitus | Chronic kidney disease stage 5 on dialysis due to type 1 diabetes mellitus |
| End stage renal disease on dialysis due to type 2 diabetes mellitus | Chronic kidney disease stage 5 on dialysis due to type 2 diabetes mellitus |
| End stage renal failure on dialysis | Chronic kidney disease stage 5 on dialysis |
| End stage renal failure with renal transplant | Chronic kidney disease stage 5 with transplant |
| End stage renal failure without renal replacement therapy | Chronic kidney disease stage 5 without renal replacement therapy |
| Endogenous | N/A |
| Endoscopic retrograde extraction of calculus from bile duct | N/A |
| Endosteal hyperostoses with cerebellar hypoplasia | Hypomyelination, hypogonadotropic hypogonadism, hypodontia syndrome |
| End-stage renal disease | Chronic kidney disease stage 5 |
| ENT domiciliary visit done | N/A |
| ENT domiciliary visit requested | N/A |
| Entire cerebellar lenticular nucleus | Entire lentiform nucleus |
| Entire delphian lymph node | N/A |
| Entire duct of Wirsung | N/A |
| Entire hypogastric lymph node | N/A |
| Entire inferior inguinal lymph node | N/A |
| Entire intervertebral disc of sacral vertebra | N/A |
| Entire lacuna of iliac fossa | N/A |
| Entire mesotendineum | N/A |
| Entire mucous gland of bronchiole | Entire bronchial mucous gland |
| Entire superior lateral inguinal lymph node | N/A |
| Entire superior medial inguinal lymph node | N/A |
| Entire tendon of flexor digiti minimi brevis of hand | N/A |
| Entire tracheal membranous wall | N/A |
| Entire valve of Hasner | N/A |
| Esophagostomy operation | N/A |
| Eutypella scoparia | N/A |
| Exogenous | N/A |
| Extensive peripapillary myelinated nerve fibers of retina | Straatsma syndrome |
| External stoma | Stoma |
| Extreme insulin resistance with acanthosis nigricans, hirsutism AND autoantibodies to the insulin receptors | N/A |
| Failed attempted termination of pregnancy complicated by damage to pelvic organ and/or tissues | Failed attempted termination of pregnancy with complication |
| Failure of exfoliation associated with ectopic eruption of succedaneous tooth | Failure of exfoliation of tooth due to ectopic eruption of succedaneous tooth |
| Failure of exfoliation associated with lack of succedaneous tooth | Failure of exfoliation of tooth due to absence of succedaneous tooth |
| Failure of tooth eruption associated with tooth impaction | Failure of eruption of tooth due to impaction of tooth |
| Familial | N/A |
| Familial adenomatous polyposis due to 5q22.2 microdeletion | Familial adenomatous polyposis |
| Familial infantile myoclonic epilepsy | Myoclonic epilepsy in infancy |
| Family Asclepiadaceae – milkweed | Apocynaceae |
| Family psychotherapy procedure | Family therapy |
| Fast acetylator due to N-acetyltransferase enzyme variant | NAT2 rapid metabolizer |
| Feature of entity | Observable entity |
| Feeding disability | N/A |
| Female to male transsexual person on hormone therapy | N/A |
| Female-to-male transsexual | Transgender male |
| Fibrosis | N/A |
| Finding of body composition | N/A |
| Finding of body product | N/A |
| Finding related to ability to dispose of household sewage | Sanitation finding |
| Finding relating to awaiting housing or re-housing | N/A |
| Fitness to drive rep sent off | N/A |
| Fitness to drive report requested | N/A |
| Fluid observable | Observable entity |
| Fluoroscopy guided percutaneous transluminal angioplasty of renal artery with contrast | N/A |
| Fluoroscopy of esophagus and stomach with gastrografin contrast swallow | Fluoroscopy of esophagus and stomach with water-soluble iodinated radiopaque contrast swallow |
| Fluoroscopy of lower gastrointestinal tract with gastrografin contrast enema | Fluoroscopy of lower gastrointestinal tract with water-soluble iodinated radiopaque contrast swallow |
| FMC-7+ cell | N/A |
| Fontan fenestration | Fontan fenestration |
| Formation of cutaneous ureterostomy | Cutaneous ureterostomy |
| Formol sublimate | Formol sublimate |
| Galactischia | Suppressed lactation |
| Gastroenterology domiciliary visit done | N/A |
| Gastroenterology domiciliary visit requested | N/A |
| Gender dysphoria in adolescence and adulthood | N/A |
| Gender identity disorder | N/A |
| Gender identity disorder of adolescence | N/A |
| Gender identity disorder of adolescence, previously heterosexual | N/A |
| Gender identity disorder of adolescence, previously homosexual | N/A |
| Gender identity disorder of adulthood | N/A |
| Gender identity disorder of adulthood, previously heterosexual | N/A |
| Gender identity disorder of adulthood, previously homosexual | N/A |
| Gender identity disorder of childhood | N/A |
| General medicine domiciliary visit done | N/A |
| General medicine domiciliary visit requested | N/A |
| General surgery domiciliary visit requested | N/A |
| General surgical domiciliary visit done | N/A |
| Generalized enamel hypoplasia associated with fluorosis | Generalized hypoplasia of enamel with fluorosis |
| Generalized enamel hypoplasia associated with ingestion of drugs | Generalized hypoplasia of enamel caused by ingestion of drug |
| Generalized enamel hypoplasia associated with radiation therapy | Generalized hypoplasia of enamel due to and following radiotherapy |
| Generalized enamel hypoplasia associated with systemic disease | N/A |
| Geriatric domiciliary visit done | N/A |
| Geriatric domiciliary visit requested | N/A |
| Giant esophagus | Congenital dilatation of esophagus |
| Giardiasis | N/A |
| Gill fluke | N/A |
| Glial tumor of brain | N/A |
| Grain-shoveller’s itch | N/A |
| Granulomatous | N/A |
| Gynecological domiciliary visit done | N/A |
| Gynecological domiciliary visit requested | N/A |
| Hallermann Streiff like syndrome | Hallermann-Streiff syndrome |
| Haloarcula algeriensis | N/A |
| Hazara hemorrhagic fever | Crimean-Congo hemorrhagic fever |
| Hazara virus | Orthonairovirus haemorrhagiae |
| Head scan abnormal | N/A |
| Helly fixative | Helly fixative |
| Herbal medicine | Plant material-containing product |
| Herbal medicine agent | N/A |
| Hereditary | N/A |
| Hereditary isolated aplastic anemia | Congenital amegakaryocytic thrombocytopenia |
| Hereditary pediatric Behçet-like disease | Early-onset autoinflammatory syndrome due to A20 haploinsufficiency |
| Heterozygous methylenetetrahydrofolate reductase mutation | Heterozygous methylenetetrahydrofolate reductase gene mutation detected |
| High body weight | N/A |
| Hip juvenile osteochondropathy | N/A |
| Home visit – no reply | N/A |
| Home visit planned by doctor | N/A |
| Home visit planned by healthcare professional | N/A |
| Homozygous methylenetetrahydrofolate reductase mutation | Homozygous methylenetetrahydrofolate reductase gene mutation detected |
| Hormonal | N/A |
| Housing report paid | N/A |
| Housing report requested | N/A |
| Housing report sent | N/A |
| Housing report status | N/A |
| Human gene | N/A |
| Human structural gene | Gene structure |
| Hydration acne | N/A |
| Hypertension concurrent and due to end stage renal disease on dialysis | Hypertension in chronic kidney disease stage 5 on dialysis |
| Hypertension concurrent and due to end stage renal disease on dialysis due to type 1 diabetes mellitus | Hypertension in chronic kidney disease stage 5 on dialysis due to type 1 diabetes mellitus |
| Hypertension concurrent and due to end stage renal disease on dialysis due to type 2 diabetes mellitus | Hypertension in chronic kidney disease stage 5 on dialysis due to type 2 diabetes mellitus |
| ICCA syndrome | Self-limited familial infantile epilepsy |
| Idiopathic chronic eosinophilic pneumonitis | N/A |
| Ilioinguinal lymph node group | N/A |
| Iliolumbar nerve injury | N/A |
| Illegitimate pregnancy | Pregnancy outside of marriage |
| Imaging of arteries of lower extremities | Angiography of artery of lower limb |
| Immunobullous disease | N/A |
| Immunology domiciliary visit done | N/A |
| Immunology domiciliary visit requested | N/A |
| Increased lung tracer uptake | N/A |
| In-exsufflator | N/A |
| Infection caused by Penicillium citreoviride | Infection caused by Penicillium citreonigrum |
| Infection caused by Pneumocystis co-occurrent with human immunodeficiency virus infection | Infection caused by Pneumocystis jirovecii with infection caused by human immunodeficiency virus |
| Infection of lung caused by Pneumocystis | Infection of lung caused by Pneumocystis jirovecii |
| Infective otitis externa due to erysipelas | Erysipelas with otitis externa caused by beta-hemolytic Streptococcus |
| Inhalational provocation test | N/A |
| Injury of lung due to vaping | N/A |
| Injury of suprarenal arteries | N/A |
| Injury undetermined whether accidentally or purposely inflicted, by crashing of motor vehicle | N/A |
| Insurance form received | N/A |
| Internal stoma | Anastomosis |
| Internal stoma fistula | Anastomotic fistula |
| Interpreter | N/A |
| Intervertebral disc of sacral vertebra | N/A |
| Intracavernous route | N/A |
| Intrinsic | N/A |
| Iodine goose quill brush | Brush |
| Irradiation fibrosis | N/A |
| Ischemic | N/A |
| Isolation of infection contact | Quarantine of infection contact |
| Isotope scan report received | N/A |
| IUD fitting awaited | N/A |
| IUD removal awaited | N/A |
| Juvenile elastofibromatosis | N/A |
| Karandikar Maria Kamble syndrome | N/A |
| Keloidalis nuchae | N/A |
| Ketosis-resistant diabetes mellitus | N/A |
| Khasan virus | Orthonairovirus haemorrhagiae |
| Lacuna of iliac fossa | N/A |
| Laryngeal hemiplegia | N/A |
| Lasègue sign | N/A |
| Lasègue test finding | N/A |
| Late postpartum state | N/A |
| Leuko-araiosis | Leukoaraiosis on imaging of brain |
| Life assurance preliminary report completed | N/A |
| Life assurance preliminary report sent off | N/A |
| Life assurance report requested | N/A |
| Life assurance report status | N/A |
| Linguist/interpreter | N/A |
| Lipoblastoma/lipoblastomatosis | N/A |
| Local orbit deformity associated with bone disorder | Orbital deformity due to bone disease |
| Local tumor spread | N/A |
| Localized cataract opacities due to and following traumatic injury | N/A |
| Localized enamel hypomineralization associated with localized trauma | Localized hypomineralization of enamel due to dental trauma |
| Localized enamel hypoplasia associated with localized trauma | Localized hypoplasia of enamel due to dental trauma |
| Lower | N/A |
| Lycopersicon esculentum | Garden tomato |
| Lymphedema due to podoconiosis | N/A |
| Lymphedematous hyperkeratosis | N/A |
| Lymphoreticular tumor | Lymphoid neoplasm |
| Lytic | N/A |
| Macular cyst of left eye | N/A |
| Macular cyst of right eye | N/A |
| Macular retinal cyst | N/A |
| Magnetic resonance imaging report received | N/A |
| Male to female transsexual person on hormone therapy | N/A |
| Male-to-female transsexual | Transgender female |
| Malignant hypertensive end stage renal disease | Malignant hypertensive chronic kidney disease stage 5 |
| Malignant hypertensive end stage renal disease on dialysis | Malignant hypertensive chronic kidney disease stage 5 on dialysis |
| Malignant mast cell neoplasm | N/A |
| Malignant neoplasm of lymphoid, hematopoietic and/or related tissue | N/A |
| Malignant otitis externa of left external auditory canal | N/A |
| Malignant otitis externa of right external auditory canal | N/A |
| Malignant otitis media | N/A |
| Mast cell malignancy | N/A |
| Masterson catheter | Cardiovascular catheter |
| Measurement of Thermoactinomyces candidus antibody | N/A |
| Medical report received | N/A |
| Medical report received from hospital | N/A |
| Medical report requested | N/A |
| Medical report sent | N/A |
| Medical reports sent | N/A |
| Megakaryocytic leukemia | N/A |
| Melanin pigmentation of oral mucosa associated with systemic condition | N/A |
| Menthol+eucalyptus inhalation | N/A |
| Mesotendineum | N/A |
| Mid postpartum state | N/A |
| Mixed glial tumor of brain | Mixed glioma of brain |
| Mixed parotid tumor | N/A |
| MNA – Mini Nutritional Assessment | N/A |
| MNA (mini nutritional assessment) score | N/A |
| Moll’s gland cyst | Cyst of ciliary gland |
| Monoclonal antibody to Orthopneumovirus hominis | Monoclonal antibody |
| Monocytoid B-cell lymphoma | N/A |
| Mucous gland of bronchiole | Bronchial mucous gland |
| Multi-organism infectious disease | N/A |
| Multiple abdominal and pelvic blood vessel injury | N/A |
| Multiple injuries of blood vessel of abdomen | N/A |
| Multiple injuries of blood vessel of pelvis | N/A |
| Myoclonic epilepsy in non-progressive encephalopathy | Developmental and epileptic encephalopathy |
| Necrotizing | N/A |
| Neoplasm of urinary bladder neck | N/A |
| Neosartorya fischeri group | N/A |
| Neurology domiciliary visit done | N/A |
| Neurology domiciliary visit requested | N/A |
| Neurosurgical domiciliary visit done | N/A |
| Neurosurgical domiciliary visit requested | N/A |
| Niemann-Pick disease, type C, acute form | N/A |
| Niemann-Pick disease, type C, chronic form | N/A |
| Niemann-Pick disease, type C, subacute form | N/A |
| Normal extracardiac tracer uptake | N/A |
| Nutcracker esophagus | Hypercontractile esophagus |
| Nystagmus signs | N/A |
| Obstetric domiciliary visit done | N/A |
| Obstetric domiciliary visit requested | N/A |
| Occupation medicine specialist | N/A |
| Oncology domiciliary visit done | N/A |
| Oncology domiciliary visit requested | N/A |
| One thousand million CFU (colony-forming units) | 10^9 colony-forming units |
| Onychomycosis caused by Scytalidium hyalinum | N/A |
| Open repair of kidney or renal pelvis | N/A |
| Ophthalmology domiciliary visit done | N/A |
| Ophthalmology domiciliary visit requested | N/A |
| Oral hairy leukoplakia associated with immunodeficiency | Oral hairy leukoplakia with immunodeficiency |
| Oral surgery domiciliary visit done | N/A |
| Oral surgery domiciliary visit requested | N/A |
| Orthopedic domiciliary visit done | N/A |
| Orthopedic domiciliary visit requested | N/A |
| Ostomy care | N/A |
| Ostomy care management | N/A |
| Ostomy collection bag | N/A |
| Outcome of benefit application awaited | N/A |
| Outer ear otoscope | N/A |
| Pachydermoperiostosis – familial | Pachydermoperiostosis syndrome |
| Pacinian schwannoma | Schwannoma |
| Papilledema of eye due to intraocular pressure below reference range | N/A |
| Pathogeneses | N/A |
| PCDH19 clustering epilepsy | PCDH19 clustering epilepsy |
| Pediatric domiciliary visit done | N/A |
| Pediatric domiciliary visit requested | N/A |
| Pediatric surgery domiciliary visit requested | N/A |
| Pediatric surgical domiciliary visit done | N/A |
| Pediculus humanus corporis | N/A |
| Pelvis juvenile osteochondropathy | Juvenile osteochondrosis of pelvis |
| Penicillium citreoviride | Penicillium citreonigrum |
| Penicillosis | Infection caused by Talaromyces marneffei |
| Peptostreptococcus barnesae | Gallicola barnesae |
| Percutaneous attention to tube in bile duct | N/A |
| Percutaneous transluminal insertion of stent into pulmonary vein | Fluoroscopy guided percutaneous transluminal insertion of stent into pulmonary vein with contrast |
| Pericarditis secondary to primary tumor | N/A |
| Perifolliculitis capitis abscedens | N/A |
| Periodontitis co-occurrent with genetic disorder | Periodontitis with genetic disorder |
| Person counseled by | N/A |
| Personal motivation | N/A |
| Phaeoseptoria | Phaeosphaeria |
| Philologist, translator AND/OR interpreter | Translator, interpreter and/or linguist |
| Physiatric hyperextension of joint | Nonsurgical manipulation of joint |
| Physiatric manipulation | Nonsurgical manipulation procedure |
| Physiatric manipulation of back | Nonsurgical manipulation of musculoskeletal structure of spine |
| Physiatric manipulation of hand | Nonsurgical manipulation of hand |
| Physiatric manipulation of lumbosacral region | Nonsurgical manipulation of musculoskeletal structure of spine |
| Physiatric manipulation of muscle structures | Nonsurgical manipulation procedure |
| Physiatric manipulation of nuchal region | Nonsurgical manipulation of cervical spine |
| Physiatric manipulation of sacroiliac region | Nonsurgical manipulation of musculoskeletal structure of spine |
| Physiatric manipulation of thoracic region | Nonsurgical manipulation of thoracic spine |
| Physiatric manipulation of wrist | Nonsurgical manipulation of joint of wrist |
| Physiatric stretching of fascia | Nonsurgical manipulation procedure |
| Physiatric stretching of muscle | Nonsurgical manipulation procedure |
| Pill esophagitis | N/A |
| Pilosebaceous apparatus | N/A |
| Plain X-ray of esophagus and stomach with gastrografin contrast swallow | Plain X-ray of esophagus and stomach with water-soluble iodinated radiopaque contrast swallow |
| Plastic reagent | N/A |
| Plastic surgery domiciliary visit done | N/A |
| Plastic surgery domiciliary visit requested | N/A |
| Pneumocystosis | Infection by Pneumocystis jirovecii |
| Pneumocystosis with AIDS (acquired immunodeficiency syndrome) | Infection caused by Pneumocystis jirovecii with acquired immunodeficiency syndrome |
| Pneumonia caused by pleuropneumonia-like organism | Pneumonia caused by Mycoplasmoides pneumoniae |
| Police surgeon’s postmortem report awaited | N/A |
| Police surgeon’s postmortem report received | N/A |
| Police surgeon’s postmortem report requested | N/A |
| Police surgeon’s postmortem report status | N/A |
| Polyneuropathy in collagen malignant disease | N/A |
| Polyneuropathy in herpes zoster | N/A |
| Posterior compartment low back pain | N/A |
| Posterior external iliac lymph node group | External iliac lymph node group |
| Postmortem report received | N/A |
| Postmortem report status | N/A |
| Postnecrotic cirrhosis | Macronodular cirrhosis |
| Postpartum period, 1 day | N/A |
| Postpartum period, 2 days | Postpartum period 25-48 hours |
| Postpartum period, 3 days | Postpartum period 49-72 hours |
| Postpartum period, 4 days | Postpartum period 73-96 hours |
| Postpartum period, 5 days | Postpartum period 97-120 hours |
| Postpartum period, 6 days | Postpartum period 121-144 hours |
| Primary gonarthrosis, bilateral | N/A |
| Primary malignant peripheral nerve sheath tumor | N/A |
| Pseudoalteromonas elyakovii | N/A |
| Pseudoalteromonas flavipulchra | N/A |
| Pseudomonas kunmingensis | N/A |
| Pseudomonas pertucinogena group | N/A |
| Pseudomonas, group VA-1 | Ralstonia pickettii biovar Va-1 |
| Pseudophakia | N/A |
| Pseudophakia of left eye | N/A |
| Pseudophakia of right eye | N/A |
| Psychiatric domiciliary visit requested | N/A |
| Psychiatry domiciliary visit done | N/A |
| Psychogeriatric domiciliary visit done | N/A |
| Psychogeriatrics domiciliary visit requested | N/A |
| Psychosexual identity disorder | N/A |
| Pulmonary medicine domiciliary visit done | N/A |
| Pulmonary medicine domiciliary visit requested | N/A |
| Pulmonary nodule caused by Pneumocystis | Nodule of lung caused by Pneumocystis jirovecii |
| Radical excision with en bloc resection of regional organs and tissues | N/A |
| Radical resection for infection of pelvis | N/A |
| Radical total vulvectomy | N/A |
| RCADS (Revised Children’s Anxiety and Depression Scale) generalized anxiety subscale | N/A |
| RCADS (Revised Children’s Anxiety and Depression Scale) Major Depressive Disorder subscale | N/A |
| RCADS (Revised Children’s Anxiety and Depression Scale) Obsessive Compulsive Disorder subscale | N/A |
| RCADS (Revised Children’s Anxiety and Depression Scale) Panic Disorder subscale | N/A |
| RCADS (Revised Children’s Anxiety and Depression Scale) Parent Version Major Depressive Disorder subscale | N/A |
| RCADS (Revised Children’s Anxiety and Depression Scale) separation anxiety subscale | N/A |
| RCADS (Revised Children’s Anxiety and Depression Scale) social phobia subscale | N/A |
| RCADS (Revised Children’s Anxiety and Depression Scale) total anxiety and depression subscale | N/A |
| RCADS (Revised Children’s Anxiety and Depression Scale) total anxiety subscale | N/A |
| RCADS-P (Revised Children’s Anxiety and Depression Scale Parent Version) generalized anxiety subscale | N/A |
| RCADS-P (Revised Children’s Anxiety and Depression Scale Parent Version) Obsessive Compulsive Disorder subscale | N/A |
| RCADS-P (Revised Children’s Anxiety and Depression Scale Parent Version) Panic Disorder subscale | N/A |
| RCADS-P (Revised Children’s Anxiety and Depression Scale Parent Version) separation anxiety subscale | N/A |
| RCADS-P (Revised Children’s Anxiety and Depression Scale Parent Version) social phobia subscale | N/A |
| RCADS-P (Revised Children’s Anxiety and Depression Scale Parent Version) total anxiety and depression subscale | N/A |
| RCADS-P (Revised Children’s Anxiety and Depression Scale Parent Version) total anxiety subscale | N/A |
| Recombinant interleukin 1 receptor antagonist | Interleukin 1 receptor antagonist |
| Recombinant interleukin 1 receptor antagonist-containing product | Interleukin 1 receptor antagonist-containing product |
| Repair AND revision of stoma of urinary bladder | Revision of stoma of urinary bladder |
| Report requested by benefits agency | N/A |
| Report status | N/A |
| Resection of non-ruptured aneurysm of carotid artery with interposition graft replacement | N/A |
| Revision of colostomy, complicated | N/A |
| Revision of ileostomy, complicated | N/A |
| Rheumatology domiciliary visit done | N/A |
| Rheumatology domiciliary visit requested | N/A |
| Rhizobium radiobacter | Agrobacterium radiobacter |
| Roseomonas ludipueritiae | Teichococcus ludipueritiae |
| Sacrococcygeal muscle | N/A |
| Sarcinosporon | N/A |
| Sarcostemma | Cynanchum |
| Sarcostemma poisoning | Cynanchum poisoning |
| Saturnine nephropathy | N/A |
| Scalenus anticus syndrome | Thoracic outlet syndrome |
| Scytalidium hyalinum | N/A |
| Scytalidium hyalinum infection of skin | N/A |
| Secondary dental caries associated with failed or defective dental restoration | N/A |
| Secondary dental caries associated with local or systemic factors | Secondary dental caries |
| Serum iron tests | Serum iron measurement |
| Signal node | N/A |
| Signet ring sign | N/A |
| Silvex | N/A |
| Single gene defect | N/A |
| Slow acetylator due to N-acetyltransferase enzyme variant | NAT2 poor metabolizer |
| Social sec report sent off | N/A |
| Social security report status | N/A |
| Sodium tetrahydride | N/A |
| Solicitors examination and report sent | N/A |
| Solicitors report requested | N/A |
| Solicitors report sent | N/A |
| Solicitors report status | N/A |
| Specimen from peritoneal tumor implant | N/A |
| Spirometra houghtonii | Spirometra mansoni |
| Spondylomalacia | N/A |
| Sporadic cretinism | Congenital hypothyroidism |
| Sprain triangular fibrocartilage | Sprain of ligament of triangular fibrocartilage complex of wrist region |
| Status post | N/A |
| Stoma bag closure | N/A |
| Stoma irrigation | N/A |
| Streptomyces plicatus | N/A |
| Structure of delphian lymph node | N/A |
| Structure of duct of Wirsung | N/A |
| Structure of hypogastric lymph node | N/A |
| Structure of inferior inguinal lymph node | N/A |
| Structure of tendon of flexor digiti minimi brevis of hand | N/A |
| Structure of tracheal membranous wall | N/A |
| Subdiaphragmatic tracer uptake | N/A |
| Superior lateral inguinal lymph node | N/A |
| Superior medial inguinal lymph node | N/A |
| Surgically transgendered transsexual | N/A |
| Surgically transgendered transsexual, female-to-male | N/A |
| Surgically transgendered transsexual, male-to-female | N/A |
| Systolic heart failure stage B | Stage B at high risk of systolic heart failure |
| Systolic heart failure stage B due to ischemic cardiomyopathy | Stage B at high risk of systolic heart failure due to ischemic cardiomyopathy |
| Temporary ileostomy | Temporary ileostomy |
| Thermoactinomyces candidus antibody | N/A |
| Thiotrichales | Beggiatoales |
| Tissue fixative | Tissue fixative |
| Tissue spot | N/A |
| Torulomyces | N/A |
| Tracheopathia osteoplastica | N/A |
| Transarterial embolization | Embolization of artery |
| Translator/interpreter | N/A |
| Transluminal right ventricular outflow tract laser operation | Transluminal laser resection of right ventricular muscle |
| Transsexual | Identifies as transgender |
| Transsexual voice | N/A |
| Ulceration of vulva associated with another disorder | N/A |
| Ulcero-granulomatous | N/A |
| Ultrasound scan report received | N/A |
| Upper | N/A |
| Urethrostomy closure | N/A |
| Urological domiciliary visit done | N/A |
| Urological domiciliary visit requested | N/A |
| Valve of Hasner | N/A |
| Van den Bosch syndrome | N/A |
| Variation in hair color | N/A |
| Virchow’s node | Enlargement of left supraclavicular lymph node |
| Vitamin A deficiency with corneal ulcer and xerosis | N/A |
| Volatile agent | N/A |
| War Pensions report requested | N/A |
| War Pensions report sent | N/A |
| War pensions report status | N/A |
| Wookey excision of esophagus with radical neck dissection | N/A |
| Word finding difficulty | N/A |
| X-linked intellectual disability Miles Carpenter type | Intellectual disability, developmental delay, contracture syndrome |
| X-linked retinal dysplasia | Atrophia bulborum hereditaria |
| X-ray evidence of poor mineralization | N/A |
| Zenker fixative | Zenker fixative |